HURATuHURA Biosciences Inc.
$2.71
$0.14
(5.45%)
Closed $2.71
$0.00
(0.00%)
After Hours
EarningsAug 13
Mkt Cap$163.66M
Vol781,022.00
Fundamentals
TuHURA Biosciences Files Investigational New Drug Application for Evaluation of the TBS-2025 VISTA Inhibiting Antibody in Molecularly Defined Subsets of AML and Other Blood Related Cancers
TuHURA Biosciences Files Investigational New Drug Application for Evaluation of the TBS-2025 VISTA Inhibiting Antibody in Molecularly Defined Subsets of AML and Other Blood Related Cancers TuHURA Biosciences Files Investigational New Drug Application for Evaluation of the TBS-2025 VISTA Inhibiting...
PR Newswire
TuHURA Biosciences Reports First Quarter 2026 Financial Results and Provides a Corporate Update
TuHURA Biosciences Reports First Quarter 2026 Financial Results and Provides a Corporate Update TuHURA Biosciences Reports First Quarter 2026 Financial Results and Provides a Corporate Update PR...
PR Newswire
TuHURA Biosciences to Present at the 4th Annual H.C. Wainwright BioConnect Investor Conference
TuHURA Biosciences to Present at the 4th Annual H.C. Wainwright BioConnect Investor Conference TuHURA Biosciences to Present at the 4th Annual H.C. Wainwright BioConnect Investor Conference PR...
PR Newswire
TuHURA Biosciences (NASDAQ:HURA) Earns Outperform Rating from Analysts at Citizens Jmp
Citizens Jmp initiated coverage on shares of TuHURA Biosciences in a report on Monday. They issued an "outperform" rating and a $9.00 price objective for the company...
MarketBeat
TuHURA Biosciences (NASDAQ:HURA) Rating Lowered to "Sell" at Wall Street Zen
Wall Street Zen lowered shares of TuHURA Biosciences from a "hold" rating to a "sell" rating in a report on Saturday...
MarketBeat
TuHURA Biosciences Announces $50 Million Credit Facility and Royalty Transaction Extending Anticipated Cash Runway into 2028
TuHURA Biosciences Announces $50 Million Credit Facility and Royalty Transaction Extending Anticipated Cash Runway into 2028 TuHURA Biosciences Announces $50 Million Credit Facility and Royalty Transaction Extending Anticipated Cash Runway into 2028 PR Newswire TAMPA, Fla., April 22, 2026 Credit...
PR Newswire
TuHURA Biosciences, Inc. (NASDAQ:HURA) Receives Consensus Rating of "Moderate Buy" from Analysts
Shares of TuHURA Biosciences, Inc. (NASDAQ:HURA - Get Free Report) have received an average recommendation of "Moderate Buy" from the four analysts that are presently covering the stock, Marketbeat...
MarketBeat
TuHURA Biosciences (NASDAQ:HURA) Raised to Hold at Wall Street Zen
Wall Street Zen upgraded TuHURA Biosciences from a "sell" rating to a "hold" rating in a research report on Wednesday...
MarketBeat
Brookline Capital Markets Comments on HURA Q1 Earnings
TuHURA Biosciences, Inc. (NASDAQ:HURA - Free Report) - Equities researchers at Brookline Capital Markets issued their Q1 2026 earnings per share estimates for TuHURA Biosciences in a research note issued on Thursday, April 9th. Brookline Capital Markets analyst K. Raja forecasts that the company wil...
MarketBeat
FY2029 EPS Forecast for TuHURA Biosciences Lifted by Analyst
TuHURA Biosciences, Inc. (NASDAQ:HURA - Free Report) - Equities research analysts at Brookline Capital Markets upped their FY2029 earnings per share (EPS) estimates for shares of TuHURA Biosciences...
MarketBeat
<
1
2
...
>
Advertisement|Remove ads.
Latest HURA News
ViewTuHURA Biosciences Files Investigational New Drug Application for Evaluation of the TBS-2025 VISTA Inhibiting Antibody in Molecularly Defined Subsets of AML and Other Blood Related Cancers
PR Newswire
TuHURA Biosciences Reports First Quarter 2026 Financial Results and Provides a Corporate Update
PR Newswire
TuHURA Biosciences to Present at the 4th Annual H.C. Wainwright BioConnect Investor Conference
PR Newswire
Advertisement|Remove ads.